ArticleBlood advances2026
Allogeneic HSCT outcomes and impact of defibrotide prophylaxis on SOS after inotuzumab in pediatric B-ALL.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractInotuzumab ozogamicin (InO) is a humanized, anti-CD22 antibody-drug conjugate with demonstrated use in the treatment of children with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). Sinusoidal obstruction syndrome (SOS), a life-threatening complication of hematopoietic stem cell transplant (HSCT), arises from injury to the sinusoidal endothelium and occurs at higher frequency and severity after treatment with InO. Defibrotide is widely used in the treatment of transplant-associated SOS; however, its role in prophylaxis is less clear. In this single-center retrospective analysis, we evaluated all children, adolescents, and young adults with relapsed or refractory B-ALL who underwent HSCT at our institution from 2016 to 2024 and compared outcomes between those who received InO during reinduction before HSCT with those who did not. In addition, we evaluated our institutional practice of employing defibrotide as SOS prophylaxis during HSCT for those with prior receipt of InO. Among children treated with InO, we found that 81% of this heavily pretreated population received InO as the last therapy before HSCT. We found no increase in nonrelapse mortality during HSCT in patients with previous receipt of InO. Among those who received defibrotide prophylaxis, we observed an incidence of transplant-related SOS similar to that observed among patients who did not receive InO during reinduction. Defibrotide prophylaxis was well tolerated, with low rates of adverse events and discontinuation. These results support the use of InO for children with relapsed or refractory B-ALL and suggest that defibrotide prophylaxis may reduce the incidence of SOS during HSCT after InO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.